SAN DIEGO, Nov. 1, 2017 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, announced today
that the company will release financial results for the third
quarter of 2017, after the market close on Wednesday, November 8, 2017.
Brian Lian, Ph.D., Viking's
president and chief executive officer, and Michael Morneau, Viking's chief financial
officer, will host a conference call to discuss financial results
and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, November 8, 2017.
To participate on the conference call, please dial (844)
850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In
addition, following the completion of the call, a telephone replay
will be accessible until November 15,
2017 by dialing (877) 344-7529 from the U.S. or (412)
317-0088 from outside the U.S. and entering conference ID #
10113999. Those interested in listening to the conference
call live via the internet may do so by visiting the Investor
Relations section of Viking's website at
www.vikingtherapeutics.com. An archive of the webcast will be
available for 30 days on the company's website at
www.vikingtherapeutics.com.
About Viking Therapeutics, Inc.
Viking Therapeutics,
Inc. is a clinical-stage biopharmaceutical company focused on the
development of novel, first-in-class or best-in-class therapies for
metabolic and endocrine disorders. The company's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. Viking has exclusive worldwide rights to a portfolio
of five therapeutic programs in clinical trials or preclinical
studies, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated. The company's clinical programs
include VK5211, an orally available, non-steroidal selective
androgen receptor modulator, or SARM, in Phase 2 development for
the treatment and prevention of lean body mass loss in patients who
have undergone hip fracture surgery, VK2809, a small molecule
thyroid beta agonist in Phase 2 development for
hypercholesterolemia and fatty liver disease, and VK0612, a
first-in-class, orally available drug candidate in Phase 2
development for type 2 diabetes. Viking is also developing
novel and selective agonists of the thyroid beta receptor for GSD
Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage
programs targeting metabolic diseases and anemia.
Follow Viking on Twitter @Viking_VKTX.
View original
content:http://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-third-quarter-2017-on-november-8-2017-300546687.html
SOURCE Viking Therapeutics, Inc.